A detailed history of Rhumbline Advisers transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 174,187 shares of ALLO stock, worth $357,083. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174,187
Previous 164,508 5.88%
Holding current value
$357,083
Previous $383,000 27.15%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.08 - $3.5 $20,132 - $33,876
9,679 Added 5.88%
174,187 $487,000
Q2 2024

Aug 01, 2024

BUY
$2.23 - $4.38 $27,814 - $54,631
12,473 Added 8.2%
164,508 $383,000
Q1 2024

May 09, 2024

BUY
$2.92 - $5.63 $17,736 - $34,196
6,074 Added 4.16%
152,035 $679,000
Q4 2023

Feb 08, 2024

BUY
$2.28 - $3.5 $15,540 - $23,856
6,816 Added 4.9%
145,961 $468,000
Q3 2023

Nov 09, 2023

SELL
$3.17 - $5.96 $16,154 - $30,372
-5,096 Reduced 3.53%
139,145 $441,000
Q2 2023

Aug 08, 2023

BUY
$4.53 - $6.74 $67,990 - $101,160
15,009 Added 11.61%
144,241 $716,000
Q1 2023

May 11, 2023

BUY
$4.92 - $8.21 $18,351 - $30,623
3,730 Added 2.97%
129,232 $638,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $11.11 $18,945 - $37,451
-3,371 Reduced 2.62%
125,502 $789,000
Q3 2022

Nov 10, 2022

BUY
$10.32 - $17.28 $104,995 - $175,806
10,174 Added 8.57%
128,873 $1.39 Million
Q2 2022

Aug 11, 2022

BUY
$6.78 - $12.28 $232,425 - $420,970
34,281 Added 40.61%
118,699 $1.35 Million
Q1 2022

May 12, 2022

SELL
$7.65 - $15.29 $42,097 - $84,140
-5,503 Reduced 6.12%
84,418 $769,000
Q4 2021

Feb 10, 2022

SELL
$13.13 - $24.52 $11,121 - $20,768
-847 Reduced 0.93%
89,921 $1.34 Million
Q3 2021

Nov 12, 2021

BUY
$21.01 - $27.64 $61,727 - $81,206
2,938 Added 3.35%
90,768 $2.33 Million
Q2 2021

Aug 05, 2021

BUY
$23.49 - $35.8 $621,733 - $947,554
26,468 Added 43.13%
87,830 $2.29 Million
Q1 2021

May 06, 2021

SELL
$25.79 - $39.02 $155,616 - $235,446
-6,034 Reduced 8.95%
61,362 $2.17 Million
Q4 2020

Feb 10, 2021

BUY
$25.24 - $43.45 $81,575 - $140,430
3,232 Added 5.04%
67,396 $1.7 Million
Q3 2020

Nov 12, 2020

SELL
$32.38 - $44.96 $382,925 - $531,696
-11,826 Reduced 15.56%
64,164 $2.42 Million
Q2 2020

Aug 13, 2020

BUY
$18.39 - $54.04 $393,656 - $1.16 Million
21,406 Added 39.22%
75,990 $3.25 Million
Q1 2020

May 06, 2020

BUY
$18.22 - $28.25 $24,779 - $38,420
1,360 Added 2.56%
54,584 $1.06 Million
Q4 2019

Feb 05, 2020

BUY
$24.82 - $31.4 $45,023 - $56,959
1,814 Added 3.53%
53,224 $1.38 Million
Q3 2019

Oct 23, 2019

BUY
$26.11 - $32.99 $3,080 - $3,892
118 Added 0.23%
51,410 $1.4 Million
Q2 2019

Aug 14, 2019

BUY
$25.56 - $31.09 $509,768 - $620,058
19,944 Added 63.62%
51,292 $1.38 Million
Q1 2019

May 01, 2019

BUY
$24.82 - $32.54 $13,899 - $18,222
560 Added 1.82%
31,348 $906,000
Q4 2018

Jan 31, 2019

BUY
$22.5 - $33.3 $692,730 - $1.03 Million
30,788 New
30,788 $829,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $295M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.